The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Smirnova N.F.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnology of the FMBA

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia;
Pirogov City Clinical Hospital No. 1

Guseva M.E.

Pirogov Russian National Research Medical University

Volkov A.I.

Federal Center of Brain and Neurotechnology of Federal Medical-Biological Agency of Russia

Ofatumumab — a new drug for the treatment of multiple sclerosis

Authors:

Boyko A.N., Smirnova N.F., Shchukin I.A., Guseva M.E., Volkov A.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2): 37‑43

DOI: 10.17116/jnevro202112107237

Read: 10680 times

Contact the author
Table of contents

OFATUMUMAB — A NEW DRUG FOR THE TREATMENT OF MULTIPLE SCLEROSIS
OFATUMUMAB — A NEW DRUG FOR THE TREATMENT OF MULTIPLE SCLEROSIS

To cite this article:

Boyko AN, Smirnova NF, Shchukin IA, Guseva ME, Volkov AI. Ofatumumab — a new drug for the treatment of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):37‑43. (In Russ.)
https://doi.org/10.17116/jnevro202112107237

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Rapi­dly progressive periodontitis. (A successful expe­rience of eighteen years of obse­rvation). Russian Journal of Stomatology. 2025;(2):61-67
Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76
Bacterial vagi­nosis: modern views. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):261-268
Method of photodynamic action in surgical treatment of local limi­ted peri­tonitis in the expe­riment. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):77-86
Appe­ndicular dive­rticulum in acute appe­ndix. Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(2-2):117-120
Abstract:

Recently anti-B-cell therapy has been increasingly integrated into the treatment of multiple sclerosis (MS). This review is devoted to ofatumumab, a new drug of this line. Ofatumumab, an all-human monoclonal antibody used to treat chronic leukemia, binds to a different region than the binding site of other CD20 antibodies, including both a small and large loop in the CD20 receptor structure. This monoclonal antibody provides favorable results for MS by reducing the frequency of exacerbations and the risk of disability progression, significantly more pronounced when compared with teriflunomide. The drug can be used in patients with active relapsing MS and SPMS with exacerbations, with the ineffectiveness of first-line drugs as one of the options for second-line therapy, in patients with highly active MS, especially with a high risk of PML (transfer from natalizumab), as well as if there are difficulties in organizing intravenous courses in day hospitals (produced as outpatient injections).

Keywords:

multiple sclerosis
treatment
anti-B-cell therapy
ofatamumab

Authors:

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Smirnova N.F.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnology of the FMBA

Shchukin I.A.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia;
Pirogov City Clinical Hospital No. 1

Guseva M.E.

Pirogov Russian National Research Medical University

Volkov A.I.

Federal Center of Brain and Neurotechnology of Federal Medical-Biological Agency of Russia

Received:

20.05.2021

Accepted:

26.05.2021

Close metadata

References:

  1. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19:696-707.  https://doi.org/10.1038/s41590-018-0135-x
  2. Blauth K, Owens GP, Bennett JL. The ins and outs of B cells in multiple sclerosis. Front Immunol. 2015;6:565.  https://doi.org/10.3389/fimmu.2015.00565
  3. Brändle SM, Obermeier B, Senel M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci USA. 2016;113:7864-7869. https://doi.org/10.1073/pnas.1522730113
  4. Rodríguez-Pinto D. B cells as antigen presenting cells. Cell Immunol. 2005;238:67-75.  https://doi.org/10.1016/j.cellimm.2006.02.005
  5. Genç K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 2007;99:2664-2671. https://doi.org/10.1172/JCI119455
  6. Staun-Ram E, Miller A. Effector and regulatory B cells in multiple sclerosis. Clin Immunol. 2017;184:11-25.  https://doi.org/10.1016/j.clim.2017.04.014
  7. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089-1104. https://doi.org/10.1093/brain/awm038
  8. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188-2197. https://doi.org/10.1056/NEJMoa1100648
  9. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-1189. https://doi.org/10.1093/brain/awp070
  10. Bharadia T, Kesselring J, Boyko A, et al. Systematic mapping of the global educational offerings for multiple sclerosis patients on the topic of disease progression. Multiple Sclerosis Journal. 2019;25(S2):384.  https://doi.org/10.2147/PPA.S268829
  11. Lisak RP, Benjamins JA, Nedelkoska L, et al. Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol. 2012;246:85-95.  https://doi.org/10.1016/j.jneuroim.2012.02.015
  12. Benjamins JA, Nedelkoska L, Touil H, et al. Exosome-enriched fractions from MS B cells induce oligodendrocyte death. Neurol Neuroimmunol Neuroinflamm. 2019;6(3):e550. https://doi.org/10.1212/NXI.0000000000000550
  13. Lisak RP, Nedelkoska L, Benjamins JA, et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J Neuroimmunol. 2017;309:88-99.  https://doi.org/10.1016/j.jneuroim.2017.05.004
  14. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J ImmunoI. 2006;177:362-371.  https://doi.org/10.4049/jimmunol.177.1.362
  15. Hauser SL, Bar-Or A, Comi G, et al. OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.  https://doi.org/10.1056/NEJMoa1601277
  16. Montalban X, Hauser SL, Kappos L, et al. ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220.  https://doi.org/10.1056/NEJMoa1606468
  17. Boyko AN, Davydovskaya MV, Khachanova NV, et al. Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(3):16-25. (In Russ.). https://doi.org/10.14412/2074-2711-2019-3-16-25
  18. Kurrasch R, Brown JC, Chu M, et al. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics. J Rheumatol. 2013;40:1089-1096. https://doi.org/10.3899/jrheum.121118
  19. Hauser SL, Bar-Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.  https://doi.org/10.1056/NEJMoa1917246
  20. Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology. 2018;90:1805-1814. https://doi.org/10.1212/WNL.0000000000005516
  21. Florou D, Katsara M, Feehan J, et al. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sci. 2020;10(10):758.  https://doi.org/10.3390/brainsci10100758
  22. Sanford M, McCormack PL. Ofatumumab Drugs. 2010;70(8):1013-1019. https://doi.org/10.2165/11203850-000000000-00000
  23. Boyko AN. Additional study of efficacy and safety of therapy in Russian population of MS patients, participated in phase III international multicentral clinical trials: data from alemtuzumab trials. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119:10(2):148-153. (In Russ.). https://doi.org/10.17116/jnevro2019119102148
  24. Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Comp Eff Res. 2020;(18):1255-1274. https://doi.org/10.2217/cer-2020-0122
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.